$2.600
-0.203 (-7.80%)Zum Schluss
Kursprognosen
In der App öffnen, um Prognosen mit längerem Horizont freizuschalten.
VRAX-Prognose durch Analyse ähnlicher Charts
Alphio's VRAX stock price prediction model matches the current Virax Biolabs Group Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.52 (-0.96%). The 1-week path is $2.51 (-1.28%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Soll ich Virax Biolabs Group Ltd-Aktien kaufen?
Currently, Virax Biolabs Group Ltd (VRAX) is not a strong buy due to its significant year-to-date decline of 70.62% and a negative forward P/E ratio of 0, indicating potential challenges in future earnings. The RSI is at 42.168, suggesting the stock is nearing oversold conditions, but the recent 5-day change of -11.60% raises concerns about short-term momentum. The main risk is its low trading volume of 37,110 compared to an average of 1,008,051, indicating a lack of investor interest and liquidity.
VRAX schloss am Tuesday bei $2.60, nachdem der Kurs -7.80% fallen
Virax Biolabs Group Ltd (VRAX) last closed at $2.545, losing -2.12%. These facts feed the 1-day and 1-week VRAX price prediction above.
Prognose-Treiber
Die Prognose-Treiber von Virax Biolabs Group Ltd (VRAX) kombinieren ähnliche Chartmuster, Saisonalität und gleitende Durchschnitte.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Ähnliche Chartmuster
Aktien, deren jüngster Kursverlauf VRAX am ähnlichsten ist, sortiert nach Ähnlichkeit.
Saisonalitätsanalyse für VRAX
Historically the probability of a positive September return for VRAX is 46.51%. November offers the highest probability of a positive month at 51.28%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.